NuVasive, Inc. (NASDAQ:NUVA) has been given an average rating of “Hold” by the twenty-one research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and ten have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $65.75.

A number of equities analysts recently commented on NUVA shares. Zacks Investment Research upgraded NuVasive from a “hold” rating to a “buy” rating and set a $54.00 price target for the company in a report on Monday, February 19th. Needham & Company LLC reiterated a “buy” rating and set a $70.00 price target (down previously from $71.00) on shares of NuVasive in a report on Tuesday, February 27th. Canaccord Genuity reduced their price target on NuVasive from $81.00 to $73.00 and set a “buy” rating for the company in a report on Tuesday, February 27th. Leerink Swann lifted their price target on NuVasive from $51.00 to $52.00 and gave the stock a “market perform” rating in a report on Tuesday, February 27th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $55.00 price target (down previously from $67.00) on shares of NuVasive in a report on Tuesday, February 27th.

Several large investors have recently modified their holdings of the company. Diversified Trust Co boosted its holdings in shares of NuVasive by 18.5% during the first quarter. Diversified Trust Co now owns 9,520 shares of the medical device company’s stock worth $497,000 after acquiring an additional 1,487 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of NuVasive by 4.3% during the first quarter. Principal Financial Group Inc. now owns 226,509 shares of the medical device company’s stock worth $11,826,000 after acquiring an additional 9,438 shares during the period. Xact Kapitalforvaltning AB raised its position in shares of NuVasive by 33.9% in the first quarter. Xact Kapitalforvaltning AB now owns 6,716 shares of the medical device company’s stock valued at $351,000 after buying an additional 1,700 shares in the last quarter. Legal & General Group Plc raised its position in shares of NuVasive by 11.3% in the first quarter. Legal & General Group Plc now owns 51,828 shares of the medical device company’s stock valued at $2,706,000 after buying an additional 5,258 shares in the last quarter. Finally, Highbridge Capital Management LLC acquired a new stake in shares of NuVasive in the first quarter valued at approximately $6,375,000.

NuVasive stock traded down $0.38 during midday trading on Thursday, reaching $52.60. 396,500 shares of the company’s stock were exchanged, compared to its average volume of 823,069. NuVasive has a 52 week low of $44.62 and a 52 week high of $81.68. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.30 and a current ratio of 2.41. The stock has a market capitalization of $2.69 billion, a P/E ratio of 27.54, a PEG ratio of 1.42 and a beta of 0.36.

NuVasive (NASDAQ:NUVA) last posted its quarterly earnings results on Tuesday, May 1st. The medical device company reported $0.39 EPS for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.06). NuVasive had a return on equity of 13.14% and a net margin of 4.14%. The business had revenue of $260.50 million for the quarter, compared to the consensus estimate of $259.43 million. During the same quarter in the previous year, the business posted $0.37 EPS. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. research analysts forecast that NuVasive will post 2.45 earnings per share for the current year.

About NuVasive

NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

Analyst Recommendations for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.